Pharmasyntez (MISK: LINE), one of Russia’s leading drugmakers, is preparing a new project in the domestic market, which involves commercial production of dialysis drugs, reports The Pharma Letter’s local correspondent.
The project is expected to be implemented in partnership with the local operations of the American firm Baxter, the main player in this market in Russia. Financial details are not disclosed.
According to local analysts, the value of investments will reach 2–3 billion roubles (~$20-$30 million). Pharmasyntez has well-developed production facilities, so launching a new project should not be associated with huge costs for the company.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze